China
Wins in court have been key to the six-year-old firm’s growth, as one of its founders explains
Loke Khoon Tan and Stephanie Yip at Dentons explain what brand owners need to know ahead of January 1 2027, when updates to China’s Trade Mark Law come into force
New US bills signal that firms should work with clients to ensure they are complying with potential regulatory requirements
Nick Redfearn, head of enforcement at Rouse and a classic car enthusiast, explains the sudden viral appearance of classic car restomod parts from China and the impact of IP in this new trade
Sponsored
Sponsored
-
Sponsored by Tahota Law FirmCharles Feng, Lian Xue, and Yetong Liu of Tahota Law Firm examine whether the model constitutes a monopolistic agreement and draw on the US approach to suggest several changes that could facilitate fair competition
-
Sponsored by Liu Shen & AssociatesGuanyang Yao of Liu, Shen & Associates highlights a revised approach to standard-essential patent protection and a recent Huawei–Netgear infringement case that exemplifies the balancing of interests between rights holders and implementers
-
Sponsored by Wanhuida Intellectual PropertyJicheng Yang and Jianhui Li of Wanhuida Intellectual Property draw on insights from CNIPA practice in discussing how different drafting approaches to crystal form patent claims impact protection scope and patent validity
-
Sponsored by Tahota Law FirmCharles Feng, Lian Xue, and Yifan Lu of Tahota Law Firm explore Beijing's pioneering role among eight Chinese provinces and municipalities designated to work on the development of the country’s data intellectual property rights framework
-
Sponsored by Tahota Law FirmCharles Feng and Lian Xue of Tahota Law Firm analyse judicial interpretations of China’s Trademark Law and explain why the date of infringement should be the starting point for the ‘preceding three years’ non-use period
-
Sponsored by Wanhuida Intellectual PropertyWu Xiaoping of Wanhuida Intellectual Property says the methodology often applied in assessing inventiveness in pharmaceutical patent litigation cases is set to be used in re-examination and invalidation proceedings after the CNIPA makes an invalidation decision a quasi-precedent